TheraBiologics is a clinical stage biopharmaceutical company developing a proprietary human neural stem cell (NSC) platform for targeted delivery of potent therapeutics to malignant tumors, with an initial focus on brain cancer.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/therabiologics-inc-” connections=”true” suffix=””]
TheraBiologics properietary TBX NSC Platform uses Neural Stem Cells (NSCs) as a vehicle to target anti-cancer payloads selectively to invasive tumor sites. TBX NSCs are engineered to stably express an enzyme (cytosine deaminase; CD) that can convert an inactive prodrug (5-flurocytosine; 5-FC) to an active chemotherapeutic agent (5-Flurouracil; 5-FU).
March 2015, GenVec, Inc. (NASDAQ: GNVC) collaborate with TheraBiologics to develop cancer therapeutics leveraging both GenVecs proprietary gene delivery platform and TheraBiologics proprietary neural stem cell (NSC) technology. Under the terms, GenVec will contribute technology, know-how, vector construction, and technical and regulatory support to the program, while TheraBiologics will be responsible for all other development costs.
Karen S. Aboody, Founder & Chief Scientific Officer, of TheraBiologics had received over $30 Mn in academic grants and gifts to develop 3 TBX NSC product candidates, TBX.OncV, TBX.CE and the underlying NSC platform TBX.CD.